# Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

> **NCT03686657** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **ARKAY Therapeutics** · enrollment: 115 (estimated)

## Conditions studied

- Type 2 Diabetes
- High Blood Pressure
- Arthritis
- Obesity

## Interventions

- **DRUG:** Metformin
- **DRUG:** Val, Cel and Met XR Low
- **DRUG:** Val, Cel and Met XR High

## Key facts

- **NCT ID:** NCT03686657
- **Lead sponsor:** ARKAY Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2028-11-26
- **Final completion:** 2029-01-31
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03686657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03686657, "Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03686657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*